Annual Shareholders Equity
$82.95 M
+$13.21 M+18.94%
December 31, 2024
Summary
- As of March 6, 2025, CRDF annual stockholders equity is $82.95 million, with the most recent change of +$13.21 million (+18.94%) on December 31, 2024.
- During the last 3 years, CRDF annual shareholders equity has fallen by -$57.47 million (-40.93%).
- CRDF annual shareholders equity is now -40.93% below its all-time high of $140.42 million, reached on December 31, 2021.
Performance
CRDF Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$82.95 M
+$33.56 M+67.94%
December 31, 2024
Summary
- As of March 6, 2025, CRDF quarterly stockholders equity is $82.95 million, with the most recent change of +$33.56 million (+67.94%) on December 31, 2024.
- Over the past year, CRDF quarterly shareholders equity has increased by +$33.56 million (+67.94%).
- CRDF quarterly shareholders equity is now -40.93% below its all-time high of $140.42 million, reached on December 31, 2021.
Performance
CRDF Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
CRDF Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.9% | +67.9% |
| 3 y3 years | -40.9% | -36.2% |
| 5 y5 years | +1034.5% | -36.2% |
CRDF Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -40.9% | +18.9% | -40.9% | +67.9% |
| 5 y | 5-year | -40.9% | +1034.5% | -40.9% | +1250.2% |
| alltime | all time | -40.9% | +1760.5% | -40.9% | +2013.9% |
Cardiff Oncology Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $82.95 M(+18.9%) | $82.95 M(+67.9%) |
| Sep 2024 | - | $49.39 M(-5.7%) |
| Jun 2024 | - | $52.39 M(-14.0%) |
| Mar 2024 | - | $60.89 M(-12.7%) |
| Dec 2023 | $69.74 M(-34.4%) | $69.74 M(-10.4%) |
| Sep 2023 | - | $77.83 M(-10.1%) |
| Jun 2023 | - | $86.58 M(-10.3%) |
| Mar 2023 | - | $96.50 M(-9.3%) |
| Dec 2022 | $106.34 M(-24.3%) | $106.34 M(-6.1%) |
| Sep 2022 | - | $113.21 M(-6.0%) |
| Jun 2022 | - | $120.47 M(-7.4%) |
| Mar 2022 | - | $130.10 M(-7.3%) |
| Dec 2021 | $140.42 M(+9.6%) | $140.42 M(+5.1%) |
| Sep 2021 | - | $133.54 M(-3.9%) |
| Jun 2021 | - | $138.92 M(+11.3%) |
| Mar 2021 | - | $124.82 M(-2.6%) |
| Dec 2020 | $128.16 M(+1652.9%) | $128.16 M(+282.3%) |
| Sep 2020 | - | $33.52 M(+37.5%) |
| Jun 2020 | - | $24.38 M(+296.9%) |
| Mar 2020 | - | $6.14 M(-16.0%) |
| Dec 2019 | $7.31 M(-27.5%) | $7.31 M(+9.8%) |
| Sep 2019 | - | $6.66 M(-24.8%) |
| Jun 2019 | - | $8.85 M(-8.7%) |
| Mar 2019 | - | $9.69 M(-3.9%) |
| Dec 2018 | $10.08 M | $10.08 M(-27.9%) |
| Sep 2018 | - | $13.98 M(-20.0%) |
| Jun 2018 | - | $17.48 M(+273.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $4.68 M(-28.1%) |
| Dec 2017 | $6.51 M(-67.1%) | $6.51 M(+64.9%) |
| Sep 2017 | - | $3.94 M(+12.4%) |
| Jun 2017 | - | $3.51 M(-67.1%) |
| Mar 2017 | - | $10.68 M(-46.0%) |
| Dec 2016 | $19.77 M(-59.4%) | $19.77 M(-26.2%) |
| Sep 2016 | - | $26.77 M(-17.8%) |
| Jun 2016 | - | $32.57 M(-20.9%) |
| Mar 2016 | - | $41.16 M(-15.5%) |
| Dec 2015 | $48.70 M(+483.3%) | $48.70 M(-11.2%) |
| Sep 2015 | - | $54.86 M(+202.8%) |
| Jun 2015 | - | $18.12 M(-23.1%) |
| Mar 2015 | - | $23.56 M(+182.2%) |
| Dec 2014 | $8.35 M(-59.1%) | $8.35 M(-32.4%) |
| Sep 2014 | - | $12.35 M(-28.7%) |
| Jun 2014 | - | $17.33 M(-2.4%) |
| Mar 2014 | - | $17.75 M(-12.9%) |
| Dec 2013 | $20.39 M(+840.2%) | $20.39 M(-3.5%) |
| Sep 2013 | - | $21.14 M(-955.4%) |
| Jun 2013 | - | -$2.47 M(-260.9%) |
| Mar 2013 | - | $1.54 M(-29.2%) |
| Dec 2012 | $2.17 M(-151.3%) | $2.17 M(-56.4%) |
| Sep 2012 | - | $4.98 M(-9.4%) |
| Jun 2012 | - | $5.49 M(-226.7%) |
| Mar 2012 | - | -$4.33 M(+2.4%) |
| Dec 2011 | -$4.23 M(-15.3%) | -$4.23 M |
| Dec 2010 | -$5.00 M | - |
FAQ
- What is Cardiff Oncology annual stockholders equity?
- What is the all time high annual shareholders equity for Cardiff Oncology?
- What is Cardiff Oncology annual shareholders equity year-on-year change?
- What is Cardiff Oncology quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Cardiff Oncology?
- What is Cardiff Oncology quarterly shareholders equity year-on-year change?
What is Cardiff Oncology annual stockholders equity?
The current annual shareholders equity of CRDF is $82.95 M
What is the all time high annual shareholders equity for Cardiff Oncology?
Cardiff Oncology all-time high annual stockholders equity is $140.42 M
What is Cardiff Oncology annual shareholders equity year-on-year change?
Over the past year, CRDF annual stockholders equity has changed by +$13.21 M (+18.94%)
What is Cardiff Oncology quarterly stockholders equity?
The current quarterly shareholders equity of CRDF is $82.95 M
What is the all time high quarterly shareholders equity for Cardiff Oncology?
Cardiff Oncology all-time high quarterly stockholders equity is $140.42 M
What is Cardiff Oncology quarterly shareholders equity year-on-year change?
Over the past year, CRDF quarterly stockholders equity has changed by +$33.56 M (+67.94%)